Study explores amla phytochemicals as potential inhibitors of Top1 protein in cancer. Aims to find alternative treatment without side effects from acetylcholinesterase inhibition. New medications could reduce irinotecan's side effects.
This study investigated the specific anticancer ingredients and mechanism of action of Sargentodoxa cuneata and Patrinia villosa in combination for colorectal cancer treatment. Results could provide insights for developing effective therapies.
Demethylzeylasteral, a natural compound derived from Tripterygium wilfordii, has shown potent anti-colon cancer activity. This study identifies S100A11 as a target protein and NF-κB as a regulator of S100A11 expression, highlighting the potential of demethylzeylasteral for anti-tumor therapy.
Docking studies identified potential inhibitors for the interaction between ceruloplasmin and myeloperoxidase, including lycoperoside F, xyloglucan oligosaccharides, and Ardimerin digallate, showing promise as inhibitors of ceruloplasmin and potential candidates for cancer treatment research.
A study analyzed O. basilicum extract and its nanoemulsion formulation, finding 22 components including Caryophyllene and Naringenin. The nanoemulsion showed potential for biomedical applications, with sustained release, low toxicity, and enhanced anticancer and antimicrobial properties. More research is needed for optimization and efficacy.
Researchers discovered that a compound called berberrubine, found in Coptis chinensis, selectively inhibits IMPDH2, a protein highly expressed in colorectal cancer. Berberrubine impairs cancer cell growth and reduces tumor size in cells and mouse models, indicating potential for CRC treatment.
Researchers investigated the effects of an ethanolic root extract of TK (ETK) on metastatic lung cancer cells resistant to EGFR tyrosine kinase inhibitors. ETK reduced migration and invasion and suppressed EMT by dephosphorylating Src. CuB played a key role in ETK's anti-metastatic activity. ETK could be a potential treatment for EGFR-TKI-resistant lung cancer.
Scientists found that morusinol, a compound from L., has potential as an anticancer agent for colorectal cancer. It inhibits cell growth, promotes cell death, and induces autophagy in cancer cells by affecting cholesterol metabolism. Animal models confirmed its ability to impede tumor growth, making it a potential candidate for CRC treatment.